AbbVie Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
August 16 2019 - 2:16PM
Dow Jones News
By Josh Beckerman
AbbVie Inc. (ABBV) said the U.S. Food and Drug Administration
has approved Rinvoq, or upadacitinib, a treatment for rheumatoid
arthritis.
The drug is expected to be available in the U.S. later this
month.
In February, AbbVie said the FDA granted priority review to its
new drug application.
The drug, an oral Janus kinase inhibitor, was approved for
adults with moderately to severely active rheumatoid arthritis who
have had an inadequate response or intolerance to methotrexate.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 16, 2019 14:01 ET (18:01 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
